Literature DB >> 23139935

A multimodal, β-amyloid-targeted contrast agent.

Sashiprabha M Vithanarachchi1, Matthew J Allen.   

Abstract

A multimodal, β-amyloid-targeted contrast agent was synthesized and studied in vitro. The agent has a higher relaxivity than a clinically approved contrast agent and interacts with β-amyloid aggregates producing changes in relaxation rate and fluorescence emission.

Mesh：

Substances：

Year:  2012        PMID： 23139935     DOI： 10.1039/c2cc36583a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  6 in total

Review 1.  Lanthanide probes for bioresponsive imaging.

Authors:  Marie C Heffern; Lauren M Matosziuk; Thomas J Meade
Journal:  Chem Rev       Date:  2013-12-13       Impact factor: 60.622

2.  Gd(3+) complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques.

Authors:  André F Martins; Jean-François Morfin; Carlos F G C Geraldes; Eva Tóth
Journal:  J Biol Inorg Chem       Date:  2013-12-03       Impact factor: 3.358

3.  Aqueous Lanthanide Chemistry in Asymmetric Catalysis and Magnetic Resonance Imaging.

Authors:  Matthew J Allen
Journal:  Synlett       Date:  2016-06       Impact factor: 2.454

4.  Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.

Authors:  André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes
Journal:  J Biol Inorg Chem       Date:  2015-11-27       Impact factor: 3.358

Review 5.  Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review.

Authors:  Jonathan Pansieri; Matthieu Gerstenmayer; François Lux; Sebastien Mériaux; Olivier Tillement; Vincent Forge; Benoit Larrat; Christel Marquette
Journal:  Nanomaterials (Basel)       Date:  2018-09-18       Impact factor: 5.076

6.  Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process.

Authors:  Rohmad Yudi Utomo; Satoshi Okada; Akira Sumiyoshi; Ichio Aoki; Hiroyuki Nakamura
Journal:  RSC Adv       Date:  2022-02-09       Impact factor: 3.361
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.